Mabion (MABP)

Warsaw
76.80
-0.50(-0.65%)
  • Volume:
    44,833
  • Bid/Ask:
    76.80/77.00
  • Day's Range:
    76.10 - 79.90

MABP Overview

Prev. Close
77.3
Day's Range
76.1-79.9
Revenue
-
Open
77.8
52 wk Range
19.5-126.2
EPS
-3.86
Volume
44,833
Market Cap
1.24B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
256,650
P/E Ratio
-
Beta
1.28
1-Year Change
116.53%
Shares Outstanding
16,161,326
Next Earnings Date
Sep 01, 2021
What is your sentiment on Mabion?
or
Vote to see community's results!

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Buy
SummaryStrong SellStrong SellStrong SellBuyStrong Buy

Mabion Company Profile

Mabion Company Profile

Employees
213
Market
Poland

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.